4/24
10:53 am
sage
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
4/24
07:10 am
sage
Registration for Association of Bioscience Financial Officers 2024 National Conference in May in Boston Nearing Full Capacity [Yahoo! Finance]
Low
Report
Registration for Association of Bioscience Financial Officers 2024 National Conference in May in Boston Nearing Full Capacity [Yahoo! Finance]
4/23
07:48 pm
sage
Ex-Stanford President's AI Drug Startup Pulls In $1 Billion in Commitments [BNN Bloomberg (Canada)]
Medium
Report
Ex-Stanford President's AI Drug Startup Pulls In $1 Billion in Commitments [BNN Bloomberg (Canada)]
4/19
11:01 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/18
01:52 pm
sage
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]
Low
Report
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]
4/18
12:09 pm
sage
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
Low
Report
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release [Yahoo! Finance]
4/18
10:23 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a "sector outperform" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $34.00 to $19.00. They now have a "sector outperform" rating on the stock.
4/18
09:06 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $25.00 to $17.00. They now have a "market perform" rating on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $25.00 to $17.00. They now have a "market perform" rating on the stock.
4/18
08:04 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/18
08:04 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $30.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $30.00 to $16.00. They now have a "buy" rating on the stock.
4/18
08:02 am
sage
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade) [Seeking Alpha]
Medium
Report
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade) [Seeking Alpha]
4/17
03:01 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $14.00 price target on the stock, down previously from $24.00.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $14.00 price target on the stock, down previously from $24.00.
4/17
02:50 pm
sage
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data [Yahoo! Finance]
Low
Report
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data [Yahoo! Finance]
4/17
07:34 am
sage
Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study [Reuters]
Low
Report
Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study [Reuters]
4/17
06:37 am
sage
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease [Yahoo! Finance]
High
Report
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease [Yahoo! Finance]
4/17
06:30 am
sage
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
High
Report
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
4/11
06:30 am
sage
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Low
Report
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
3/28
06:49 am
sage
We're Keeping An Eye On Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Rate [Yahoo! Finance]
3/26
08:12 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
3/15
01:02 pm
sage
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? [Yahoo! Finance]
2/28
01:09 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at Morgan Stanley from $20.00 to $22.00. They now have an "equal weight" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at Morgan Stanley from $20.00 to $22.00. They now have an "equal weight" rating on the stock.
2/28
06:30 am
sage
Sage Therapeutics to Present at Upcoming March Investor Conferences
Low
Report
Sage Therapeutics to Present at Upcoming March Investor Conferences
2/27
11:13 am
sage
Huntington's Disease Treatment Market Size to Worth USD 1,217.10 Million by 2032 [Yahoo! Finance]
Low
Report
Huntington's Disease Treatment Market Size to Worth USD 1,217.10 Million by 2032 [Yahoo! Finance]
2/15
10:03 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/15
02:54 pm
sage
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates [Yahoo! Finance]